Bellicum Pharmaceuticals Stock Working Capital
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
Bellicum Pharmaceuticals fundamentals help investors to digest information that contributes to Bellicum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Bellicum Pink Sheet. The fundamental analysis module provides a way to measure Bellicum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellicum Pharmaceuticals pink sheet.
Bellicum |
Bellicum Pharmaceuticals Company Working Capital Analysis
Bellicum Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Bellicum Pharmaceuticals Working Capital | 20.03 M |
Most of Bellicum Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellicum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Bellicum Pharmaceuticals has a Working Capital of 20.03 M. This is 95.29% lower than that of the Biotechnology sector and 96.28% lower than that of the Health Care industry. The working capital for all United States stocks is 98.65% higher than that of the company.
Bellicum Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellicum Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellicum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics of similar companies.Bellicum Pharmaceuticals is currently under evaluation in working capital category among its peers.
Bellicum Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (19.69) % | |||
| Current Valuation | (38.62 M) | |||
| Shares Outstanding | 9.5 M | |||
| Shares Owned By Insiders | 4.19 % | |||
| Shares Owned By Institutions | 29.30 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | 8.50 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5.46 X | |||
| Revenue | 1.5 M | |||
| Gross Profit | (17.38 M) | |||
| EBITDA | (28.93 M) | |||
| Net Income | (24.97 M) | |||
| Cash And Equivalents | 33.17 M | |||
| Cash Per Share | 3.85 X | |||
| Total Debt | 58 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | (1.11) X | |||
| Cash Flow From Operations | (25.78 M) | |||
| Short Ratio | 0.17 X | |||
| Earnings Per Share | (1.57) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.57 | |||
| Market Capitalization | 3.52 M | |||
| Total Asset | 23.82 M | |||
| Retained Earnings | (575.42 M) | |||
| Working Capital | 20.03 M | |||
| Current Asset | 96.89 M | |||
| Current Liabilities | 7.45 M | |||
| Z Score | -0.31 | |||
| Net Asset | 23.82 M |
About Bellicum Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellicum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellicum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellicum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |